Phase III Randomized Adjuvant Study of Exemestane Versus Anastrozole Versus Tamoxifen in Hormone-Responsive Postmenopausal Breast Cancer Patients.

Trial Profile

Phase III Randomized Adjuvant Study of Exemestane Versus Anastrozole Versus Tamoxifen in Hormone-Responsive Postmenopausal Breast Cancer Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Anastrozole (Primary) ; Exemestane (Primary) ; Tamoxifen (Primary)
  • Indications Early breast cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms TEAM-Japan
  • Most Recent Events

    • 24 Jul 2012 Status changed from active, no longer recruiting to completed, based on final results reported in Breast Cancer Res Treat.
    • 01 May 2012 Final (1-year) results published in the Breast Cancer Research and Treatment.
    • 27 Mar 2010 Results of effects of exemestane and anastrozole on bone mineral density presented at the 7th European Breast Cancer Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top